Vanguard Capital Management
LUCD icon

Vanguard Capital Management’s Lucid Diagnostics LUCD Stock Holding History

Vanguard Capital Management’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.02M Buy
6,556,344
+2,401,574
+58% +$2.59M ﹤0.01% 2989
2026
Q1 		$4.78M Buy
+4,154,770
New +$5.29M ﹤0.01% 3080

Other funds holding LUCD

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Vanguard Capital Management's LUCD Position: Q2 2026 in Review

Vanguard Capital Management increased its Lucid Diagnostics (LUCD) stake by 58% in Q2 2026, buying an estimated $2.59M and bringing the position to 6,556,344 shares worth $7.02M. The position accounts for ﹤0.01% of the portfolio, ranked #2989.

Vanguard Capital Management first reported a position in LUCD in Q1 2026 and has held it in 2 quarters since. 113 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.

  • Vanguard Capital Management held 6,556,344 shares of Lucid Diagnostics worth $7.02M as of Q2 2026.
  • Vanguard Capital Management bought 2,401,574 Lucid Diagnostics shares in Q2 2026, an estimated $2.59M.
  • Lucid Diagnostics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2989 holding.
  • Vanguard Capital Management first reported a position in Lucid Diagnostics in Q1 2026 and has held it in 2 quarters since.
  • 113 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.